E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To pilot a multicentre morbidity and mortality study of treating type 2 diabetes in asymptomatic patients over the age of 75. Patients will be randomised to receive oral hypoglaecymic drugs or no drugs. The endpoints of the pilot study are the number of patients that withdraw from active treatment due to adverse effects and the number of the control patients who are admitted with ketoacidosis or hyperosmolar coma. The pilot study will also test the recruitment strategy, data collection, adverse biochemical events and hyperglycaemic control. The end point rates are 10%, 100 patients in each group will give 95% confidence levels of 4.9%, 17.6% with 80% power. The ultimate aim is to establish the risk to benefit ratio of using oral hypoglycaemic agents in the very elderly in a full trial. |
|
E.2.2 | Secondary objectives of the trial |
We will collect data on the development of diabetes-related complications including infection rates, hospital admissions and weight changes. |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1) Men and women over the age of 75 at the time of randomisation. 2) After 2 months of dietary treatment, a HbA1c equal to or greater than 7.5 - equal to or less than 9.0%. 3) Informed written consent. 4) No symptom due to uncontrolled diabetes such as recent weight loss, polyuria, thirst or recurrent infection. 5) No serious diabetic complication such as proliferative retinopathy or sight threatening retinopathy. 6) No serious cardiovascular event in the previous 2 months. 7) No life threatening disease which is likely to lead to an early demise. 8) If previously treated with anti diabetic drugs these should have been stopped at least 2 months previously. 9) Abbreviated Mental Test Score (MTS) >=7 out of 10 of 5 or 6 the carer to also give informed assent. 10) Inclusion for metformin treatment i) serum creatinine <130umol/1 ii) no alcohol abuse (normal liver transaminases) iii) no congestive heart failure (doses of up to 40mg of Frusemide or equivalent acceptable). iv) no liver disease (normal transaminases) v) any B12 deficiency must be corrected. |
|
E.4 | Principal exclusion criteria |
1) Age less than 75 years. 2) Patient with terminal illness. 3) Presence of symptoms due to uncontrolled diabetes (recent weight loss, polyuria, thirst or recurrent infection). 4) Serious diabetic complication (proliferative retinopathy, sight threatening retinopathy). 5) Serious cardiovascular event in the previous 2 months. 6) Life threatening disease which is likely to lead to early demise. 7) Previous demonstration of a definite need for good blood sugar control eg. lactic acidosis. 8) Unable to provide informed written consent or consent withheld by the principal carer.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Adverse drug effect rates (hypoglycaemic episodes and severe side effects such as serious gastrointestinal disturbances). 2. The development of keto-acidosis or hyperosmolar diabetic coma. 3. The development of lactic acidosis. 4. The number requiring hypoglycaemic treatment due to symptoms such as thirst, polyuria and persistent infections. 5. Development of diabetic complications, retinal bleeds, renal failure, or persistent foot infections. 6. Hospital admissions due to diabetes or a diabetes-related event. 7. Weight change greater than 10% of baseline. 8. The following will be recorded but not part of the primary analysis: number of morbid or mortal cardiovascular events; total mortality.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Open blinded end points design |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The last visit of the last subject undergoing the trial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |